Revefenacin interactions
Full monograph for RevefenacinCheck it against another medicine
Medicines
99 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Abiraterone Acetate | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aripiprazole | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Artesunate | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Atropine Sulfate (Injection) | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Bempedoic acid | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Bempedoic acid + Ezetimibe | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Bethanechol Chloride | Moderate | Antagonism | Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may… | 2 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Chlorpheniramine Maleate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Chlorpromazine Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Cinnarizine + Dimenhydrinate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Clomipramine Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Clozapine | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Cyclizine Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Cyclobenzaprine Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Daclatasvir | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Daclatasvir + Sofosbuvir | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Darifenacin | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Darolutamide | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Dextromethorphan + Phenylephrine + Triprolidine | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Dextromethorphan + Pseudoephedrine + Triprolidine | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Dicycloverine Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Diphenhydramine + Dextromethorphan + Levomenthol | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Diphenhydramine + Levomenthol | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Diphenhydramine Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Diphenhydramine Hydrochloride + Zinc Acetate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Doxepin (Oral) | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Doxepin (Topical) | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Eltrombopag Olamine | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Eluxadoline | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Enasidenib | Moderate | Distribution | Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion… | 3 sources — open the full entry |
| Fesoterodine Fumarate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Flavoxate Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Fluphenazine + Nortriptyline | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary…2 documented mechanisms | 12 sources — open the full entry |
| Fluphenazine Decanoate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Formoterol Fumarate + Glycopyrrolate + Budesonide | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Gemfibrozil | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active… | 7 sources — open the full entry |
| Glecaprevir + Pibrentasvir | Moderate | Metabolism | Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active…2 documented mechanisms | 7 sources — open the full entry |
| Glycopyrronium BromideInhalation capsuleInjectionOral solutionRespirator Solution | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Guaifenesin + Levomenthol + Diphenhydramine | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Haloperidol | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
| Homatropine Hydrobromide | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 8 sources — open the full entry |
| Hydroxyzine Hydrochloride | Moderate | Synergy | The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary… | 12 sources — open the full entry |
Conditions
Conditions in which Revefenacin needs care, as documented in this source.
Glaucoma
ModerateRevefenacin should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g. eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.
1 source
- "Product Information. Yupelri (revefenacin)." Mylan Specialty (2018):
Hepatic Insufficiency
ModerateThe systemic exposure of revefenacin is unchanged while that of its active metabolite is increased in subjects with moderate hepatic impairment. The safety of revefenacin has not been evaluated in COPD patients with mild-to-severe hepatic impairment, therefore revefenacin is not recommended in patients with any degree of hepatic impairment.
1 source
- "Product Information. Yupelri (revefenacin)." Mylan Specialty (2018):
Kidney Failure, Chronic
ModerateNo dosage adjustment is required in patients with renal impairment, however, patients with severe renal impairment should be monitored for systemic antimuscarinic side effects.
1 source
- "Product Information. Yupelri (revefenacin)." Mylan Specialty (2018):
Urinary Retention
ModerateRevefenacin should be used with caution in patients with urinary retention. Health care providers and patients should be alert for signs and symptoms of urinary retention (e.g. difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder neck obstruction. Instruct patients to consult a healthcare provider immediately if any of these signs or symptoms develops.
1 source
- "Product Information. Yupelri (revefenacin)." Mylan Specialty (2018):
Therapeutic duplication
Drug classes that overlap with Revefenacin, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phenohytro
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Olodaterol/tiotropium
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Urolet mb
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Chlorpheniramine/methscopolamine/phenylephrine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Phosphasal
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/indacaterol
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Sympak ii
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Motofen
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Librax
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Trelegy ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): B & o supprettes
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Butabarbital/hyoscyamine/phenazopyridine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Hyoscyamine/phenyltoloxamine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duaklir pressair
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Duodote
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Tussigon
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Budesonide/formoterol/glycopyrrolate
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Albuterol/ipratropium
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Vi-atro
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Anoro ellipta
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Glycopyrrolate/neostigmine
anticholinergics/antispasmodics
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category.
Example product in the source data (US market): Prosed ds